JP2015091235A5 - - Google Patents

Download PDF

Info

Publication number
JP2015091235A5
JP2015091235A5 JP2014237731A JP2014237731A JP2015091235A5 JP 2015091235 A5 JP2015091235 A5 JP 2015091235A5 JP 2014237731 A JP2014237731 A JP 2014237731A JP 2014237731 A JP2014237731 A JP 2014237731A JP 2015091235 A5 JP2015091235 A5 JP 2015091235A5
Authority
JP
Japan
Prior art keywords
polynucleotide
ros fusion
sample
lung cancer
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014237731A
Other languages
English (en)
Japanese (ja)
Other versions
JP6144247B2 (ja
JP2015091235A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015091235A publication Critical patent/JP2015091235A/ja
Publication of JP2015091235A5 publication Critical patent/JP2015091235A5/ja
Application granted granted Critical
Publication of JP6144247B2 publication Critical patent/JP6144247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014237731A 2007-10-18 2014-11-25 ヒト非小細胞肺癌における転座および変異rosキナーゼ Active JP6144247B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99966807P 2007-10-18 2007-10-18
US60/999,668 2007-10-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010529983A Division JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017093754A Division JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Publications (3)

Publication Number Publication Date
JP2015091235A JP2015091235A (ja) 2015-05-14
JP2015091235A5 true JP2015091235A5 (enExample) 2015-06-25
JP6144247B2 JP6144247B2 (ja) 2017-06-07

Family

ID=40568038

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010529983A Active JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2014237731A Active JP6144247B2 (ja) 2007-10-18 2014-11-25 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2017093754A Pending JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2019100258A Pending JP2019176862A (ja) 2007-10-18 2019-05-29 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010529983A Active JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017093754A Pending JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2019100258A Pending JP2019176862A (ja) 2007-10-18 2019-05-29 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Country Status (8)

Country Link
US (4) US9096855B2 (enExample)
EP (3) EP3072963B1 (enExample)
JP (4) JP5769968B2 (enExample)
AU (4) AU2008314567B2 (enExample)
CA (1) CA2702686C (enExample)
DK (1) DK2203558T3 (enExample)
ES (1) ES2576650T3 (enExample)
WO (1) WO2009051846A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP3072963B1 (en) * 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
JP5861244B2 (ja) 2010-06-22 2016-02-16 公益財団法人がん研究会 新規ros1融合体の検出法
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
CN105229164B (zh) * 2013-03-15 2019-02-12 爱科谱迅病理研究公司 指示癌症疗法的srm测定
US10208354B2 (en) 2013-08-07 2019-02-19 Universität Zu Köln NRG1 fusion genes in cancer
JP6696908B2 (ja) 2014-04-25 2020-05-20 エグゼリクシス, インコーポレイテッド 肺腺癌の治療方法
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
WO1986000991A1 (en) 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE449853T1 (de) 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
AT400722B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante cladosporium herbarum allergene
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6083711A (en) 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
EP1038016A2 (en) 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
WO2002095059A2 (en) 2001-05-17 2002-11-28 The Public Health Research Institute Of The City Of New York, Inc. Selection of target sites for antisense attack of rna
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2002323139A1 (en) 2001-08-14 2003-03-03 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20070136825A1 (en) 2001-09-18 2007-06-14 Wolf-Bernd Frommer Fusion proteins useful for detecting analytes
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体rosキナーゼ
DE602007004998D1 (de) 2006-08-25 2010-04-08 Dow Global Technologies Inc Herstellung telecheler verbindungen durch metathesen-depolymerisierung
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma

Similar Documents

Publication Publication Date Title
CN112020562B (zh) 基于crispr效应系统的诊断
CN111108220B (zh) 用于病毒检测的基于crispr效应系统的诊断
JP2019196400A5 (enExample)
JP2015156872A5 (enExample)
JP2012518421A5 (enExample)
JP2017501685A5 (enExample)
AU2017258619A1 (en) Sequencing method employing ternary complex destabilization to identify cognate nucleotides
CN110506128A (zh) 基于crispr效应系统的诊断
JP2014204730A5 (enExample)
JP2017507130A5 (enExample)
JP2016195614A5 (enExample)
JP2015096066A5 (enExample)
JP2016509833A5 (enExample)
RU2016112354A (ru) Нуклеиново-кислотный зонд
EP3105324B1 (en) Ngs systems control and methods involving the same
JP2014530011A5 (enExample)
JP2018516594A5 (enExample)
EP2935617A1 (en) Probability-directed isolation of nucleotide sequences (pins)
JP2017512204A5 (enExample)
RU2471872C1 (ru) Способ дифференциации штаммов yersinia pestis различных подвидов и биоваров методами полимеразной цепной реакции и мультилокусного сиквенс-типирования
US9863009B2 (en) Sequence specific primer pool for multiplex PCR and method of detecting microbial infections in thalassemia patients
JP2011502487A5 (enExample)
TWI531654B (zh) 用於鑑別h5禽流感病毒病原性之寡核酸探針、含其之套組及方法
CN110225979A (zh) 基于滚环扩增的基因组目标区域富集方法及其应用
JP2014168466A5 (enExample)